A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for phase III development in postmenopausal osteoporosis, and the offset of effect on biomarkers and BMD [EXTENSION OF 700004435]

Trial Profile

A 2-year extension to study 2203, partially randomized, double-blind, placebo-controlled in the first year and open label in the second year, to assess the safety of the dose of AAE581 selected for phase III development in postmenopausal osteoporosis, and the offset of effect on biomarkers and BMD [EXTENSION OF 700004435]

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Balicatib (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 20 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top